Endo Int'l (ENDP) Closes Par Pharma Acquisition; Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
RBC Capital Cuts Price Target on Endo Int'l (ENDP) Following Guidance Update
September 29, 2015 7:42 AM EDTRBC Capital maintained a Top Pick rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $100.00 (from $107.00), following a guidance update. ENDP pointed to a 3Q range of $720-740 million in revenue which is 4% below consensus at the midpoint.
Analyst... More
Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
September 28, 2015 11:24 AM EDTGuggenheim reiterated a Buy rating and $110.00 price target on Endo International plc (NASDAQ: ENDP) following the company's updated financial guidance. Analyst Louise Chen continues to believe ENDP has set the stage for better-than-expected growth in '16+ driven by Xiaflex, Belbuca and the generics... More
